Sanetra Krzysztof, Gerber Witold, Mazur Marta, Kubaszewska Marta, Pietrzyk Ewa, Buszman Piotr Paweł, Kaźmierczak Paweł, Bochenek Andrzej
Division of Cardiovascular Surgery, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.
Department of Cardiac Surgery, American Heart of Poland, Bielsko-Biała, Poland.
Braz J Cardiovasc Surg. 2024 Feb 5;39(1):e20220346. doi: 10.21470/1678-9741-2022-0346.
The evidence for using del Nido cardioplegia protocol in high-risk patients with reduced ejection fraction undergoing isolated coronary surgery is insufficient.
The institutional database was searched for isolated coronary bypass procedures. Patients with ejection fraction < 40% were selected. Propensity matching (age, sex, infarction, number of grafts) was used to pair del Nido (Group 1) and cold blood (Group 2) cardioplegia patients. Investigation of biomarker release, changes in ejection fraction, mortality, stroke, perioperative myocardial infarction, composite endpoint (major adverse cardiac and cerebrovascular events), and other perioperative parameters was performed.
Matching allowed the selection of 45 patient pairs. No differences were noted at baseline. After cross-clamp release, spontaneous sinus rhythm return was observed more frequently in Group 1 (80% vs. 48.9%; P=0.003). Troponin values were similar in both groups 12 and 36 hours after surgery, as well as creatine kinase at 12 hours. A trend favored Group 1 in creatine kinase release at 36 hours (median 4.9; interquartile range 3.8-9.6 ng/mL vs. 7.3; 4.5-17.5 ng/mL; P=0.085). Perioperative mortality, rates of myocardial infarction, stroke, or major adverse cardiac and cerebrovascular events were similar. No difference in postoperative ejection fraction was noted (median 35.0%; interquartile range 32.0-38.0% vs. 35.0%; 32.0-40.0%; P=0.381). There was a trend for lower atrial fibrillation rate in Group 1 (6.7% vs. 17.8%; P=0.051).
The findings indicate that del Nido cardioplegia provides satisfactory protection in patients with reduced ejection fraction undergoing coronary bypass surgery. Further prospective trials are required.
在射血分数降低的高危患者接受单纯冠状动脉手术时,使用德尔尼多心脏停搏方案的证据不足。
检索机构数据库中的单纯冠状动脉搭桥手术病例。选择射血分数<40%的患者。采用倾向匹配法(年龄、性别、梗死情况、移植血管数量)对使用德尔尼多心脏停搏液的患者(第1组)和冷血心脏停搏液的患者(第2组)进行配对。对生物标志物释放情况、射血分数变化、死亡率、中风、围手术期心肌梗死、复合终点(主要不良心脏和脑血管事件)及其他围手术期参数进行研究。
匹配后选出45对患者。基线时两组无差异。松开血管夹后,第1组更频繁地观察到自发窦性心律恢复(80%对48.9%;P=0.003)。术后12小时和36小时两组肌钙蛋白值相似,术后12小时肌酸激酶值也相似。术后36小时肌酸激酶释放有倾向于第1组的趋势(中位数4.9;四分位间距3.8 - 9.6 ng/mL对7.3;4.5 - 17.5 ng/mL;P=0.085)。围手术期死亡率、心肌梗死发生率、中风发生率或主要不良心脏和脑血管事件发生率相似。术后射血分数无差异(中位数35.0%;四分位间距32.0 - 38.0%对35.0%;32.0 - 40.0%;P=0.381)。第1组房颤发生率有降低趋势(6.7%对17.8%;P=0.051)。
研究结果表明,德尔尼多心脏停搏液在射血分数降低的患者接受冠状动脉搭桥手术时能提供满意的心肌保护。需要进一步的前瞻性试验。